{"id":4094,"date":"2025-06-16T11:46:00","date_gmt":"2025-06-16T09:46:00","guid":{"rendered":"https:\/\/www.access2meds.eu\/?p=4094"},"modified":"2025-06-16T11:46:04","modified_gmt":"2025-06-16T09:46:04","slug":"take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines","status":"publish","type":"post","link":"https:\/\/www.access2meds.eu\/nl\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/","title":{"rendered":"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines"},"content":{"rendered":"\n<p>The survey focuses on access-based pricing of medicinal products. It seeks to gather insights from all stakeholders on the price determinants for new products, and how these can be applied to inform and operationalise the ASCERTAIN Pricing Model.<\/p>\n\n\n\n<p>This model, currently in development, builds on <a href=\"https:\/\/fairpricingcalculator.eu\/\">AIM\u2019s Fair Pricing Calculator<\/a> and is designed as a publicly available tool for payers, HTA bodies, healthcare professionals, industry, and patient representatives. Its goal is to balance patient access, the financial sustainability of health systems, and incentives for innovation.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\" id=\"h-survey-details\">Survey Details<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Deadline: 18 July 2025<\/li>\n\n\n\n<li>Duration: 10\u201315 minutes<\/li>\n\n\n\n<li>Responses are fully anonymous<\/li>\n\n\n\n<li>Link: <a href=\"https:\/\/lse.eu.qualtrics.com\/jfe\/form\/SV_2mjs1k5CGysSWX4\">ASCERTAIN | Survey on pricing of medicinal products<\/a><\/li>\n<\/ul>\n\n\n\n<p>Your expertise and perspective as part of the pharmaceutical pricing and reimbursement community are essential to shaping a model that is both practical and impactful.<\/p>\n\n\n\n<p>If you have any questions or wish to receive a PDF version of the questionnaire in advance, feel free to contact the ASCERTAIN Pricing Team: <a href=\"mailto:xander@eshpm.eur.nl\">xander@eshpm.eur.nl<\/a> | <a href=\"mailto:Maximilian.Salcher@goeg.at\">Maximilian.Salcher@goeg.at<\/a> | <a href=\"mailto:anne.hendrickx@solidaris.be\">anne.hendrickx@solidaris.be<\/a><\/p>\n\n\n\n<p><strong>Thank you for your valuable contribution!<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This survey is part of the ASCERTAIN Project and will remain open until 18 July 2025.<\/p>\n","protected":false},"author":5,"featured_media":1450,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[21,14,22,23,20],"class_list":["post-4094","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-allgemein","tag-health-technologies","tag-healthcare","tag-hta","tag-iht","tag-innovative-health-technologies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.8 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Take Part in Our Survey on Access-Based Pricing for Innovative Medicines - ASCERTAIN<\/title>\n<meta name=\"description\" content=\"On 2 April 2025, Myeloma Patients Europe (MPE) hosted a webinar titled &quot;How do different countries make decisions on reimbursing new medicines?&quot;. The session provided valuable insights into how European health systems approach reimbursement processes, cost-effectiveness, and patient access to new treatments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines\" \/>\n<meta property=\"og:description\" content=\"On 2 April 2025, Myeloma Patients Europe (MPE) hosted a webinar titled &quot;How do different countries make decisions on reimbursing new medicines?&quot;. The session provided valuable insights into how European health systems approach reimbursement processes, cost-effectiveness, and patient access to new treatments.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T09:46:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-16T09:46:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2005\" \/>\n\t<meta property=\"og:image:height\" content=\"1254\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Lena Jessen\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"Lena Jessen\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/\"},\"author\":{\"name\":\"Lena Jessen\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/person\\\/84cb4791d2eba62e68ecb7f29dba9391\"},\"headline\":\"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines\",\"datePublished\":\"2025-06-16T09:46:00+00:00\",\"dateModified\":\"2025-06-16T09:46:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/\"},\"wordCount\":182,\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"keywords\":[\"health technologies\",\"healthcare\",\"HTA\",\"iht\",\"innovative health technologies\"],\"articleSection\":[\"Allgemein\"],\"inLanguage\":\"nl-NL\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/\",\"name\":\"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines - ASCERTAIN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"datePublished\":\"2025-06-16T09:46:00+00:00\",\"dateModified\":\"2025-06-16T09:46:04+00:00\",\"description\":\"On 2 April 2025, Myeloma Patients Europe (MPE) hosted a webinar titled \\\"How do different countries make decisions on reimbursing new medicines?\\\". The session provided valuable insights into how European health systems approach reimbursement processes, cost-effectiveness, and patient access to new treatments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/04\\\/iStock-825537944_Liderina-scaled-e1680608197278.jpg\",\"width\":2005,\"height\":1254},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/person\\\/84cb4791d2eba62e68ecb7f29dba9391\",\"name\":\"Lena Jessen\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines - ASCERTAIN","description":"On 2 April 2025, Myeloma Patients Europe (MPE) hosted a webinar titled \"How do different countries make decisions on reimbursing new medicines?\". The session provided valuable insights into how European health systems approach reimbursement processes, cost-effectiveness, and patient access to new treatments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/","og_locale":"nl_NL","og_type":"article","og_title":"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines","og_description":"On 2 April 2025, Myeloma Patients Europe (MPE) hosted a webinar titled \"How do different countries make decisions on reimbursing new medicines?\". The session provided valuable insights into how European health systems approach reimbursement processes, cost-effectiveness, and patient access to new treatments.","og_url":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/","og_site_name":"ASCERTAIN","article_published_time":"2025-06-16T09:46:00+00:00","article_modified_time":"2025-06-16T09:46:04+00:00","og_image":[{"width":2005,"height":1254,"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","type":"image\/jpeg"}],"author":"Lena Jessen","twitter_card":"summary_large_image","twitter_creator":"@ASCERTAIN_EU","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Geschreven door":"Lena Jessen","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/#article","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/"},"author":{"name":"Lena Jessen","@id":"https:\/\/www.access2meds.eu\/#\/schema\/person\/84cb4791d2eba62e68ecb7f29dba9391"},"headline":"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines","datePublished":"2025-06-16T09:46:00+00:00","dateModified":"2025-06-16T09:46:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/"},"wordCount":182,"publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"image":{"@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","keywords":["health technologies","healthcare","HTA","iht","innovative health technologies"],"articleSection":["Allgemein"],"inLanguage":"nl-NL"},{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/","url":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/","name":"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines - ASCERTAIN","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","datePublished":"2025-06-16T09:46:00+00:00","dateModified":"2025-06-16T09:46:04+00:00","description":"On 2 April 2025, Myeloma Patients Europe (MPE) hosted a webinar titled \"How do different countries make decisions on reimbursing new medicines?\". The session provided valuable insights into how European health systems approach reimbursement processes, cost-effectiveness, and patient access to new treatments.","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/iStock-825537944_Liderina-scaled-e1680608197278.jpg","width":2005,"height":1254},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/take-part-in-our-survey-on-access-based-pricing-for-innovative-medicines\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/nl\/startpagina\/"},{"@type":"ListItem","position":2,"name":"Take Part in Our Survey on Access-Based Pricing for Innovative Medicines"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]},{"@type":"Person","@id":"https:\/\/www.access2meds.eu\/#\/schema\/person\/84cb4791d2eba62e68ecb7f29dba9391","name":"Lena Jessen"}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/posts\/4094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/comments?post=4094"}],"version-history":[{"count":1,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/posts\/4094\/revisions"}],"predecessor-version":[{"id":4095,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/posts\/4094\/revisions\/4095"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/media\/1450"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/media?parent=4094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/categories?post=4094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/tags?post=4094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}